The AI Change That Let Pfizer’s Albert Bourla Sleep Better ...

Pfizer Inc ($PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is running a Phase 3 study called “AN INTERVENTIONAL PHASE 3 STUDY TO ...

Pfizer outlook improves beyond COVID as cost cuts target $2.7B by 2029, though patents and pricing pose risks.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...

Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or ...

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Pfizer (PFE) stock has returned 17.5% over the past three months, easily outpacing the 3.7% return for the S&P 500. The board ...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

The company is entering what could be a particularly challenging period.

Pfizer will cut around 330 jobs in Italy at its Sicily plant, ​labour unions said on Wednesday, making ‌the US drugmaker the ...